medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2009, Number 1

<< Back Next >>

Ann Hepatol 2009; 8 (1)

Virological techniques for the diagnosis and monitoring of hepatitis B and C

Chevaliez S, Pawlotsky JM

Language: Spanish
References: 53
Page: 7-12
PDF size: 116.62 Kb.


Text Extraction

Approximately 500 million people, i.e. one fifth of the world population, are chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV). Each year, over 1.5 million people die from HBV- and/or HCV-related chronic liver diseases, such as end-stage cirrhosis and hepatocellular carcinoma (HCC). HCC is one of the most common cancers worldwide and in 2002, HBV and HCV have been responsible for at least half a million of these cancers.


REFERENCES

  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.

  2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.

  3. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044.

  4. Gish RG, Locarnini SA. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 2006; 4: 666-676.

  5. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36: S65-73.

  6. Sertoz RY, Erensoy S, Pas S, Akarca US, Ozgenc F, Yamazhan T, Ozacar T, et al. Comparison of sequence analysis and Inno-LiPA HBV DR line probe assay in patients with chronic hepatitis B. J Chemother 2005; 17: 514-520.

  7. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003; 43: 788-798.

  8. Gibb R, Nimmo GR, O’Loughlin P, Lowe P, Drummond D. Detection of HBsAg mutants in a population with a low prevalence of hepatitis B virus infection. J Med Virol 2007; 79: 351-355.

  9. Muhlbacher A, Weber B, Burgisser P, Eiras A, Cabrera J, Louisirirotchanakul S, Tiller FW, et al. Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants. Med Microbiol Immunol 2008; 197: 55-64.

  10. Weber B, Van der Taelem-Brule N, Berger A, Simon F, Geudin M, Ritter J. Evaluation of a new automated assay for hepatitis B surface antigen (HBsAg) detection Vidas HBsAg Ultra. J Virol Methods 2006; 135: 109-117.

  11. Weber B, Bayer A, Kirch P, Schluter V, Schlieper D, Melchior W. Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. J Clin Microbiol 1999; 37: 2639-2647.

  12. Weber B, Dengler T, Berger A, Doerr HW, Rabenau H. Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: Immulite HBsAg and Immulite 2000 HBsAg. J Clin Microbiol 2003; 41: 135-143.

  13. Shukla NB, Poles MA. Hepatitis B virus infection: co-infection with hepatitis C virus, hepatitis D virus, and human immunodeficiency virus. Clin Liver Dis 2004; 8: 445-460.

  14. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-1097.

  15. Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, Lee PC, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006; 130: 1625-1635.

  16. Akhan SC, Yulugkural Z, Vahaboglu H. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers. Chemotherapy 2007; 53: 402-406.

  17. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-1468.

  18. Ozaras R, Tabak F, Tahan V, Ozturk R, Akin H, Mert A, Senturk H. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. Dig Dis Sci 2008; 53: 2995-2998.

  19. Chevaliez S, Bouvier-Alias M, Laperche S, Pawlotsky JM. Performance of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 2008; 46: 1716-1723.

  20. Thibault V, Pichoud C, Mullen C, Rhoads J, Smith JB, Bitbol A, Thamm S, et al. Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections. J Clin Microbiol 2007; 45: 3948-3953.

  21. Hussain M, Chu CJ, Sablon E, Lok AS. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol 2003; 41: 3699-3705.

  22. Gintowt AA, Germer JJ, Mitchell PS, Yao JD. Evaluation of the MagNA Pure LC used with the Trugene HBV Genotyping Kit. J Clin Virol 2005; 34: 155-157.

  23. Libbrecht E, Doutreloigne J, Van De Velde H, Yuen MF, Lai CL, Shapiro F, Sablon E. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. J Clin Microbiol 2007; 45: 3935-3941.

  24. Osiowy C, Villeneuve JP, Heathcote EJ, Giles E, Borlang J. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the Inno-LiPA HBV DR line probe assay (version 2). J Clin Microbiol 2006; 44: 1994-1997.

  25. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936-962.

  26. Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346: 1682-1683.

  27. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-861.

  28. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.

  29. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.

  30. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.

  31. Chen CJ, Yang HI, Su J, Jen CL, You SL, Chen CF, Iloeje UH. Serial monitoring of viral load and serum alanine transferase level and the risk of hepatocellular carcinoma (HCC): REVEAL-HBV study update. J Hepatol 2008; 48(Suppl. 2): S61.

  32. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; in press.

  33. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008; 134: 405-415.

  34. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007; 147: 58-61.

  35. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.

  36. Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C, Razer A, Lefrere JJ, Pawlotsky JM, et al. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the Inno-LiPA HCV assay. J Clin Microbiol 2007; 45: 1140-1145.

  37. Chevaliez S, Bouvier-Alias M, Vandervenet C, Pawlotsky JM. HCV genotype determination in clinical practice: weaknesses of assays based on the 5’noncoding region and improvement with the core-coding region. Hepatology 2007; 46(Suppl.1): 839A.

  38. Stelzl E, van der Meer C, Gouw R, Beld M, Grahovac M, Marth E, Kessler HH. Determination of the hepatitis C virus subtype: comparison of sequencing and reverse hybridization assays. Clin Chem Lab Med 2007; 45: 167-170.

  39. Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, Wollants E, Morimoto J, et al. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 2008; 46: 1901-1906.

  40. Pawlotsky JM, Prescott L, Simmonds P, Pellet C, Laurent-Puig P, Labonne C, Darthuy F, et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol 1997; 35: 1734-1739.

  41. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007; 46: 22-31.

  42. Chevaliez S, Bouvier-Alias M, Pawlotsky JM. Performance of the Abbott m2000SP/m2000RT real-time polymerase chain reaction assay for hepatitis C virus RNA quantification. Submitted.

  43. Lok AS, Chien D, Choo QL, Chan TM, Chiu EK, Cheng IK, Houghton M, et al. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993; 18: 497-502.

  44. Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000; 38: 575-577.

  45. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46.

  46. Hadziyannis SJ, Sette H Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.

  47. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, Crespo J, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-460.

  48. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 1260-1265.

  49. Ferenci P, Bergholz U, Laferl H, Scherzer TM, Maieron A, Gschwantler M, Brunner H, et al. 24 weeks treatment regimen with peginterferon alpha-2a (40 kDa) (Pegasys) plus ribavirin (Copegus) in HCV genotype 1 or 4 «super-responders». J Hepatol 2006; 44: S6.

  50. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-2617.

  51. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-527.

  52. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.

  53. Fried MW, Hadziyannis SJ, Shiffman M, Messinger D, Zeuzem S. Rapide virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection. J Hepatol 2008; 48: S5.




2020     |     www.medigraphic.com